Scarica l'app Stockscreener
1.97
2.50%
-0.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.00
Aprire:
$2.01
Volume 24 ore:
124.65K
Relative Volume:
4.90
Capitalizzazione di mercato:
$23.03M
Reddito:
$3.02M
Utile/perdita netta:
$-653.00K
Rapporto P/E:
-39.96
EPS:
-0.0493
Flusso di cassa netto:
$2.42M
1 W Prestazione:
-8.88%
1M Prestazione:
-5.80%
6M Prestazione:
+12.07%
1 anno Prestazione:
+75.68%
Intervallo 1D:
$1.94
$2.02
Intervallo di 1 settimana:
$1.87
$2.124
Portata 52W:
$0.9811
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Nome
Therapeuticsmd Inc
Settore
Telefono
561-961-1900
Indirizzo
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
1.9899 | 23.15M | 3.02M | -653.00K | 2.42M | -0.0493 |
TAK
Takeda Pharmaceutical Co Adr
|
15.61 | 48.82B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.51 | 40.09B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.125 | 39.63B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.77 | 33.34B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
546.61 | 23.25B | 3.17B | 1.29B | 1.01B | 27.09 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-08-07 | Downgrade | Jefferies | Hold → Underperform |
| 2020-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Iniziato | Guggenheim | Buy |
| 2019-10-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-04-30 | Ripresa | Noble Capital Markets | Outperform |
| 2018-06-15 | Iniziato | JP Morgan | Overweight |
| 2017-09-08 | Iniziato | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Downgrade | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Ripresa | Jefferies | Buy |
| 2016-11-22 | Iniziato | Oppenheimer | Outperform |
| 2016-11-07 | Ripresa | Guggenheim | Buy |
| 2016-04-04 | Iniziato | Goldman | Buy |
| 2015-12-08 | Reiterato | Jefferies | Buy |
| 2015-12-08 | Reiterato | Stifel | Buy |
| 2015-09-21 | Reiterato | Jefferies | Buy |
| 2015-06-09 | Iniziato | Guggenheim | Buy |
| 2014-07-08 | Iniziato | FBR Capital | Outperform |
| 2014-04-17 | Reiterato | Noble Financial | Buy |
| 2014-01-28 | Reiterato | Noble Financial | Buy |
Mostra tutto
Therapeuticsmd Inc Borsa (TXMD) Ultime notizie
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TXMD Stock Price, Quote & Chart | THERAPEUTICSMD INC (NASDAQ:TXMD) - ChartMill
TXMD Q3 2023 Earnings: EPS Misses Estimates, Stock DeclinesPost-Earnings Drift - newsline.com
TXMD Q3 2023 Earnings: A Significant EPS Miss Amid No Reported RevenueLow Growth Earnings - newsline.com
TherapeuticsMD (TXMD) Edges Higher as Support Holds Near $2.01Post-Earnings Moves - Newser
What TherapeuticsMD TXMD flagged as biggest challenges ahead Q3 2023 EPS Misses ViewsBanking Earnings Report - The Legal Advocate
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TherapeuticsMD Announces First Quarter 2026 Financial Results - BioSpace
TXMD Reports Strong Q1 Revenue Growth and Explores Strategic Alt - GuruFocus
Is TherapeuticsMD (TXMD) 13.4% Overvalued After Q1 2026 Earnings - GuruFocus
[10-Q] TherapeuticsMD, Inc. Quarterly Earnings Report - Stock Titan
TherapeuticsMD Reports Quarterly Profit, Evaluates Strategic Alternatives - TipRanks
TherapeuticsMD: Q1 Earnings Snapshot - marketscreener.com
TherapeuticsMD swings to Q1 net income as license revenue rises - TradingView
TherapeuticsMD (TXMD) details Q1 2026 results and strategic review - Stock Titan
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
What TherapeuticsMD (TXMD) flagged as biggest challenges ahead | Q3 2023: EPS Misses ViewsStock Trading Network - Newser
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
TXMD Should I Buy - Intellectia AI
TXMD (TherapeuticsMD Inc.) posts far wider Q3 2023 loss than expected, with shares dipping 0.48% in today’s trading.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD (TherapeuticsMD Inc.) Q3 2023 EPS misses consensus estimates by wide margin as shares dip 0.48 percent in today's trading.Trending Stock Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD Financials: Income Statement, Balance Sheet & Cash Flow | Therapeuticsmd Inc - Stock Titan
TXMD (TherapeuticsMD) shares gain 5.8 percent despite wider than expected Q3 2023 per share loss.Earnings Revision Report - Newser
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Total debt per share of TherapeuticsMD, Inc. – MUN:29TA - TradingView — Track All Markets
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
Therapeuticsmd Inc Azioni (TXMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.32%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):